Structure-based molecular insights into matrix metalloproteinase inhibitors in cancer treatments.

Haili Lin, Peng Xu, Mingdong Huang

Future medicinal chemistry 2022 Jan

filter terms:

Protease inhibitors are of considerable interest as anticancer agents. Matrix metalloproteinases (MMPs) were the earliest type of proteases considered as anticancer targets. The developments of MMP inhibitors (MMPIs) by pharmaceutical companies can be dated from the early 1980s. Thus far, none of the over 50 MMPIs entering clinical trials have been approved. This work summarizes the reported studies on the structure of MMPs and complexes with ligands and inhibitors, based on which, the authors analyzed the clinical failures of MMPIs in a structural biological manner. Furthermore, MMPs were systematically compared with urokinase, a protease-generating plasmin, which plays similar pathological roles in cancer development; the reasons for the clinical successes of urokinase inhibitors and the clinical failures of MMPIs are discussed.

Citation

Haili Lin, Peng Xu, Mingdong Huang. Structure-based molecular insights into matrix metalloproteinase inhibitors in cancer treatments. Future medicinal chemistry. 2022 Jan;14(1):35-51